Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Phase 2b funding option amount Phase2bFundingOptionAmount Phase 2b funding option amount. Maximum Maximum [Member] Beneficial interest obtained in exchange for securitized accounts receivables Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset Sustainability-linked senior notes EUR 1,500 million Sustainability Linked Senior Notes Due 2030 [Member] Sustainability linked senior notes due 2030. Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Title of 12(b) Security Title of 12(b) Security Net income (loss) attributable to Teva’s ordinary shareholders Net Income (Loss) Available to Common Stockholders, Diluted Subsequent event Subsequent Event [Member] Weighted average interest rate Debt, Weighted Average Interest Rate Adjustment to Compensation, Amount Adjustment to Compensation Amount Income Tax [Line Items] Income Tax [Line Items] Income Tax [Line Items] Segment Reporting [Abstract] Employee-related obligations Employee-related Liabilities, Current Accrued amount for legal settlements and loss contingencies Loss Contingency Accrual Derivative Instrument [Axis] Derivative Instrument [Axis] Provision Restructuring Accrual Provision Restructuring Accrual Provision Proceeds from sale of businesses and long-lived assets, net Proceeds from Divestiture of Businesses Transactions termination loss settled Transactions Termination Loss Settled Transactions termination loss settled. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Settlement as a percentage of aggregate subdivisions and tribes Settlement As A Percentage Of Aggregate Subdivisions And Tribes Settlement as a percentage of aggregate subdivisions and tribes. Other assets impairments, restructuring and other items Other assets impairments, restructuring and other items Impairments Restructuring And Others Impairments restructuring and others. Amortization Amortization Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Claims dismissed Loss Contingency, Claims Dismissed, Number Common stock, par value (in ILS per share) Common Stock, Par or Stated Value Per Share Asset Acquisition [Axis] Asset Acquisition [Axis] Long-term liabilities: Liabilities, Noncurrent [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Products in process Inventory, Work in Process, Net of Reserves Generic pipeline products Generic Pipeline Products [Member] Generic Pipeline Products [Member] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Entity Address, City or Town Entity Address, City or Town Christine Fox [Member] Christine Fox Statement of Financial Position [Abstract] Percentage sales reserves and allowances to U.S. customers Sales Reserves and Allowances to Customers Percentage Sales reserves and allowances to customers percentage. Distribution Distribution Service [Member] Sale of goods Product [Member] Identifiable intangible assets, net Net carrying amount Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Opioid Litigation, Anda Opioid Litigation, Anda [Member] Opioid Litigation, Anda Deferred prosecution agreement with U.S. Department of Justice Deferred Prosecution Agreement With U.S. Department of Justice [Member] Deferred prosecution agreement with U.S. department of justice. Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Licensing arrangements License [Member] United States UNITED STATES Other non-current assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Fine for violating the antitrust laws Fine for Violating the Antitrust Laws [Member] Fine for violating the antitrust laws. Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Goodwill allocation related to the shift of Anda to Other Activities Revision of Prior Period, Reclassification, Adjustment [Member] Amended revolving credit facility Amended Revolving Credit Facility [Member] Amended revolving credit facility member. Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Period End Date Document Period End Date Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Other commitment to pay for each year Other Commitment to Pay for Each Year Other commitment to pay for each year. Debt instrument face amount Debt Instrument, Face Amount Reconciliation of Segment Revenues by Major Products and Activities Segment Reporting, Reconciliation of Revenue by Segment to Consolidated [Table Text Block] Weighted average interest rate Debt Instrument, Interest Rate, Effective Percentage Legal settlements and loss contingencies Legal Settlements And Loss Contingencies The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items). Returns Returns [Member] Returns. Abingworth Abingworth [Member] Abingworth [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Consolidation Items [Domain] Consolidation Items [Domain] Tax settlement Effective Income Tax Rate Reconciliation, Tax Settlement, Amount Earnings (loss) per share Earnings Per Share [Text Block] Earnings (loss) per share attributable to ordinary shareholders: Earnings Per Share [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Attorneys general lawsuits Loss Contingency, Attorneys General Lawsuits Loss Contingency, Attorneys General Lawsuits Total liabilities Liabilities Trading Symbol Trading Symbol Measurement input, discount rate Measurement Input, Discount Rate [Member] Number of additional candidates Number of Additional Candidates Number of Additional Candidates Company Selected Measure Name Company Selected Measure Name Income Tax Disclosure [Abstract] Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Shares (denominator): Earnings Per Share, Diluted [Abstract] Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Valsartan Valsartan [Member] Valsartan Credit Facility [Domain] Credit Facility [Domain] Operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration] Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration] International Markets International Markets [Member] International markets. Cross currency interest rate swap Cross Currency Interest Rate Contract [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Disposal Group Name [Domain] Disposal Group Name [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Summary of Major Classes of Assets and Liabilities Included as Held for Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Translation differences Valuation Allowances And Reserves Foreign Currency Translation Valuation allowances and reserves foreign currency translation. Gross profit Gross Profit Goodwill Goodwill [Text Block] Customers involved Loss Contingency, Number of Customers Involved Loss Contingency, Number of Customers Involved Award Timing Predetermined Award Timing Predetermined [Flag] MedinCell MedinCell [Member] MedinCell [ Member]. Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] PNC Bank PNC Bank [Member] PNC bank. AUSTEDO Austedo [Member] Austedo [Member] Aggregate upfront and milestone payments Aggregate Upfront And Milestone Payments Aggregate Upfront And Milestone Payments. Total Impairment And Restructuring Impairment and restructuring. Depreciation Depreciation Accounts receivables Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Scenario [Domain] Scenario [Domain] Deferred income taxes Deferred Tax and Other Liabilities, Noncurrent Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Other Legal Settlements Loss Contingencies Impairments Other Expenses Legal settlements loss contingencies impairments other expenses. Fair Value Disclosures [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Expiration Date Trading Arrangement Expiration Date Cross-currency interest rate swap-cash flow hedge Cross Currency Swap Cash Flow Hedge [Member] Cross Currency Swap Cash Flow Hedge. Cash and cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Option and forward contracts Not Designated as Hedging Instrument, Trading [Member] Disposal Group, Including Discontinued Operations [Line Items] Disposal Group, Including Discontinued Operations [Line Items] Loss contingency aggregate payments paid Loss Contingency Aggregate Payments Paid Loss contingency aggregate payments paid. Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivative [Table] Derivative [Table] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Product Information [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Litigation Status [Axis] Litigation Status [Axis] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Sustainability-linked senior notes USD 1,000 million Sustainability Linked Senior Notes Due 2027 [Member] Sustainability linked senior notes due 2027. Segments [Domain] Segments [Domain] Milestone payment two Milestone Payment, Payment Two Milestone Payment, Payment Two Debt obligations Debt Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Convertible preferred stock Convertible Preferred Stock [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Maturity Debt Instrument Maturity Year Debt Instrument Maturity Year Summary of Restructuring Accruals Restructuring and Related Costs [Table Text Block] Business Combination [Table] Business Combination [Table] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Accounts payables Accounts Payable, Trade, Current Number of years spread to pay tax payable Number Of Years Spread To Pay Tax Payable Number of years spread to pay tax payable. Equity, Attributable to Parent Equity, Attributable to Parent Other Other Exit And Disposal [Member] Other exit and disposal. ASSETS Assets [Abstract] Legal settlements and loss contingencies Legal Settlements And Loss Contingencies Unallocated To Segments The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items). Adjustments to provisions for contingent consideration: Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Provision Adjustments Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease. Less current maturities Senior Notes, Current Insider Trading Policies and Procedures [Line Items] Sustainability-linked senior notes USD 500 million Sustainability Linked Senior Notes Due 2031 [Member] sustainability linked senior notes due 2031. Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Number of operating Segments Number of Operating Segments Diluted effect of stock options, RSUs and PSUs (in shares) Weighted average shares with anti-dilutive effect on earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Summary of Changes in the Carrying Amount of Goodwill by Segment Goodwill [Table Text Block] Entity Central Index Key Entity Central Index Key Civil investigative demand from department of Justice Civil Division Civil Investigative Demand From Department Of Justice Civil Division [Member] Civil investigative demand from department of justice civil division. Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Foreign currency translation attributable to non-controlling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Legal settlements and loss contingencies Legal Matters and Contingencies [Text Block] Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets Disposal Group, Including Discontinued Operation, Liabilities Loss contingency accrual due in third year Loss Contingency Accrual Due In Year Three Loss contingency accrual due in year three. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Designated as hedging instruments Designated as Hedging Instrument [Member] Sustainability-linked senior notes EUR 800 million Sustainability Linked Senior Notes Due 2029 Two [Member] Sustainability linked senior notes due 2029 two. 2025 Two Thousand And Twenty Five [Member] Two thousand and twenty five. Accumulated other comprehensive income (loss) Total AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Accounts payables Disposal Group, Including Discontinued Operation, Accounts Payable Classes of Direct Purchaser Plaintiffs Filed Claims Classes of Direct Purchaser Plaintiffs Filed Claims Classes of Direct Purchaser Plaintiffs Filed Claims Balance at beginning of period Balance at end of period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Finished products Inventory, Finished Goods, Net of Reserves Previously reported Previously Reported [Member] Identifiable intangible assets Intangible Asset [Text Block] Statement [Line Items] Statement [Line Items] Total assets Assets November 2023 November Two Thousand And Twenty Three [Member] November Two Thousand And Twenty Three [Member] European Commission Surety underwritten guarantees European Commission Surety Underwritten Guarantees European Commission Surety Underwritten Guarantees Business Combination [Abstract] Maximum tax payment limit Maximum Tax Payment Limit Maximum tax payment limit. Convertible Debt Convertible Debt [Member] AJOVY AJOVY [Member] AJOVY [Member] Operating segments Operating Segments [Member] PEO PEO [Member] Senior notes USD 1,000 million Senior Notes USD 1000 Million, Due 2037 [Member] Senior Notes USD 1000 Million, Due 2037 Other taxes and long-term liabilities Other Liabilities, Noncurrent Goodwill Beginning balance Ending balance Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Discount rate applied to cash flows, percentage Percentage Of Discount Rate Applied To The Cash Flows Percentage Of Discount Rate Applied To The Cash Flows Initial commitment Initial Commitment [Member] Initial Commitment. Retained earnings (accumulated deficit) Retained Earnings [Member] Operating lease liabilities Operating Lease, Liability, Noncurrent Money markets Money Market Funds [Member] Revolving credit facility Revolving Credit Facility [Member] Development progress and changes in other key valuation assumptions Development Progress And Changes In Other Key Valuation Assumptions [Member] Development progress and changes in other key valuation assumptions. Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Award Timing Disclosures [Line Items] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Diluted (in dollars per share) Diluted earnings (loss) attributable to Teva’s ordinary shareholders (in dollars per share) Earnings Per Share, Diluted Rebates Rebates [Member] Rebates. Senior notes and convertible senior debentures included under short-term debt Senior Notes And Convertible Senior Debentures [Member] Senior notes and convertible senior debentures. Litigation Case [Domain] Litigation Case [Domain] Amortization of intangible assets Intangible Asset, Finite-Lived, Amortization Expense Stockholders' Equity Note [Abstract] Intangible Asset, Finite-Lived [Line Items] Intangible Asset, Finite-Lived [Line Items] 2024 Two Thousand And Twenty Four [Member] Two thousand and twenty four. Incremental common shares attributable to dilutive effect of conversion of preferred stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Net revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Period [Axis] Period [Axis] Period axsis. Teva's API business Teva API Business [Member] Teva's API business. Repayment of senior notes and loans and other long-term liabilities Repayments of Other Long-Term Debt Schedule of Other Assets Impairments, Restructuring and Other Items Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Financial expenses, net Unrealized Gain (Loss) on Cash Flow Hedging Instrument Unrealized gain (loss) on cash flow hedging instrument. Valuation allowance Asset Acquisition, Valuation Allowance Asset Acquisition, Valuation Allowance Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant, and Equipment, Current Operating income (loss) Operating income (loss) Operating Income (Loss) Collaboration partner funding reimbursements Collaboration Partner Funding Reimbursements Collaboration Partner Funding Reimbursements Senior notes and sustainability-linked senior notes included under senior notes and loans Senior Notes And Sustainability Linked Senior Notes [Member] Senior notes and sustainability linked senior notes. Respiratory products Respiratory Product [Member] Respiratory product. Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Equity securities Equity Securities [Member] Basic earnings (loss) attributable to Teva’s ordinary shareholders (numerator): Net Income (Loss) Available to Common Stockholders, Basic, Operations [Abstract] United States United States Segment [Member] United States Segment [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Ordinary shares, issued (in shares) Common Stock, Shares, Issued Repaid amount Debt Instrument, Repaid, Principal BioXcel Therapeutics BioXcel Therapeutics [Member] BioXcel Therapeutics Product and Service [Domain] Product and Service [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Exit And Disposal [Axis] Exit And Disposal [Axis] Exit And Disposal [Axis] Venlafaxine Venlafaxine [Member] Venlafaxine Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Termination Date Trading Arrangement Termination Date Other Commitments [Axis] Other Commitments [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Total reserves included in Sales Reserves and Allowances Total Reserves Included In Sales Reserves And Allowances [Member] Total reserves included in sales reserves and allowances. Agreement milestone payments Agreement Milestone Payments Agreement milestone payments. Statutory tax rate in Israel Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Other current liabilities Other Liabilities, Current Senior notes EUR 500 million Senior Notes EUR 500 Million, Due 2036 [Member] Senior Notes EUR 500 Million, Due 2036 Amarin, Vascepa drug Amarin, Vascepa Drug [Member] Amarin, Vascepa Drug Fair Value as of Grant Date Award Grant Date Fair Value Schedule of Goodwill [Table] Goodwill [Table] Provisions related to sales made in current year period Valuation Allowances And Reserves Related To Current Period Sales Valuation allowances and reserves related to current period sales. Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Product rights Identifiable product rights Product Rights [Member] Product Rights [Member] Arrangement Duration Trading Arrangement Duration Consolidation Items [Axis] Consolidation Items [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Biolojic Design Biolojic Design Ltd [Member] Biolojic design ltd. Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Acquired in-process research and development Research And Development Expense And Liabilities Research And Development Expense And Liabilities Gross carrying amount net of impairment Intangible Asset, Finite-Lived, before Accumulated Amortization Share in (profits) losses of associated companies, net Income (Loss) from Equity Method Investments Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Goodwill [Roll Forward] Goodwill [Roll Forward] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Dividends paid to redeemable and non-redeemable non-controlling interests Dividends Paid To Non controlling Interests Dividends paid to noncontrolling interests. Trade names Trade Names [Member] Former shareholders milestone payment Former Shareholders Milestone Payment [Member] Former Shareholders Milestone Payment Summary of Financial Items Carried at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Supplier finance program obligation Supplier Finance Program, Obligation All Award Types Award Type [Domain] Fair value measurement Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Loss contingency accrual next twelve months Loss Contingency Accrual Next Twelve Months Loss contingency accrual next twelve months. Lamictal Lamictal [Member] Annual sales of Lamictal. Geographical [Axis] Geographical [Axis] Provisions related to sales made in prior periods Valuation Allowances And Reserves Related To Prior Period Sales Valuation allowances and reserves related to prior period sales. Long term debt currency portion USD Long Term Debt Currency Portion U S D Long term debt currency portion U S D. Senior notes USD 3,500 million Subsidiary Senior Notes Due 2026 [Member] subsidiary senior notes due 2026. Short-Term Debt [Table] Short-Term Debt [Table] Number of instances Loss Contingency Number of Instances Loss Contingency Number of Instances Credits and payments SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Liability Class [Axis] Liability Class [Axis] Balance of cash and cash equivalents at beginning of period Balance of cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Loss contingency accrual due in fifth year Loss Contingency Accrual Due In Fifth Year Loss contingency accrual due in fifth year. Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Loss contingency accrual, product liability, undiscounted, to be paid, year five Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Five Non-NEOs Non-NEOs [Member] Payments to acquire businesses Payments to Acquire Businesses, Gross Niaspan Niaspan [Member] Niaspan Europe Europe Segment [Member] Europe segment. Summary of Inventories Schedule of Inventory, Current [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Goodwill Disposal Group, Including Discontinued Operation, Goodwill, Current Senior notes EUR 700 million Subsidiary Senior Notes Due 2027 [Member] Subsidiary senior notes due 2027. Range [Axis] Statistical Measurement [Axis] Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Truvada Truvada [Member] Annual sales of the time of settlement of truvada. Agreement [Axis] Agreement [Axis] Agreement. Senior notes EUR 1,000 million Senior notes EUR 1000 Million, Due 2031 [Member] Senior notes EUR 1000 Million [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Equity securities Equity Securities, FV-NI Contingent consideration Business combination contingent consideration arrangements change in amount of contingent consideration liability Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Short-Term Debt [Line Items] Short-Term Debt [Line Items] Ordinary shares Common Stock [Member] Employee termination Employee Severance [Member] Legal settlements and loss contingencies, expenses Litigation Settlement, Fee Expense Effective income tax rate reconciliation, tax settlement, other, percent Effective Income Tax Rate Reconciliation, Tax Settlement, Other, Percent Option and forward contracts economic hedge Not Designated as Hedging Instrument, Economic Hedge [Member] Senior notes USD 1,250 million Subsidiary Senior Notes Due 2028 [Member] Subsidiary senior notes due 2028. mAbxience mAbxience [Member] mAbxience. Reserves included in Accounts Receivable, net Reserves Included In Accounts Receivable Net [Member] Reserves included in accounts receivable net. Derivative Contract [Domain] Derivative Contract [Domain] Translation differences and other Goodwill, Foreign Currency Translation, Gain (Loss) Total liabilities and equity Liabilities and Equity Employee Stock Option Share-Based Payment Arrangement, Option [Member] Amounts reclassified to the statements of income Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Non-controlling interests Equity, Attributable to Noncontrolling Interest Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Asset Class [Axis] Asset Class [Axis] Restructuring Restructuring charges Restructuring Charges Tabular List, Table Tabular List [Table Text Block] Net income (loss), including portion attributable to noncontrolling interest and mezzanine Items Net Income (Loss), Including Portion Attributable to Noncontrolling Interest and Mezzanine Items Net income loss including noncontrolling interest. Additional paid-in capital Additional Paid in Capital Other loss (income) Other Other Operating Income (Expense), Net Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Senior notes USD 2,000 million Subsidiary Senior Notes Due 2046 [Member] Subsidiary senior notes due 2046. Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Intangible assets impairments Intangible Assets Impairments Intangible Assets Impairments SPV amendment agreement October 2024 SPV Amendment Agreement October Two Thousand And Twenty Four [Member] SPV Amendment Agreement October Two Thousand And Twenty Four [Member] Materials in transit and payments on account Other Inventory, in Transit, Gross Senior notes EUR 1,000 million Senior Notes EUR 1000 Million, Due 2033 [Member] Senior Notes EUR 1000 Million, Due 2033 Other assets impairments, restructuring and other items Other Expenses [Text Block] Other Expenses [Text Block] Receivable for sale of long-lived assets Receivable For Sale of Long-Lived Assets Receivable For Sale of Long-Lived Assets Adjustment to Compensation: Adjustment to Compensation [Axis] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Purchases of property, plant and equipment and intangible assets Payments to acquire assets Payments to Acquire Productive Assets Extinguishment of debt Extinguishment of Debt, Amount Lilly Galcanezumab product Lilly Galcanezumab Product [Member] Lilly Galcanezumab Product Hedging Designation [Axis] Hedging Designation [Axis] ADS to ordinary shares, conversion ratio American Depositary Shares To Ordinary Shares, Conversion Ratio American Depositary Shares To Ordinary Shares, Conversion Ratio Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Abstract] Credit Facility [Axis] Credit Facility [Axis] Loss contingency accrual, product liability, undiscounted, to be paid, year one Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year One Name Measure Name Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Number of candidates Number of Candidates Number of Candidates Debt Instrument [Line Items] Debt Instrument [Line Items] Blackstone Life Sciences Blackstone Life Sciences [Member] Blackstone Life Sciences [Member] Other assets Increase (Decrease) in Other Current Assets Opioid litigation Opioid Litigation [Member] Opioid Litigation [Member] Senior notes USD 789 million Subsidiary Senior Notes USD 789 million, due 2036 [Member] Subsidiary senior notes due 2036. Additional paid-in capital Additional Paid-in Capital [Member] Repayments of convertible senior debentures Repayments of Short-Term Debt Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalent Nuvigil Nuvigil [Member] Claims settled Loss Contingency, Claims Settled, Number Raw and packaging materials Inventory, Raw Materials, Net of Reserves Company Selected Measure Amount Company Selected Measure Amount Schedule of Segment Information Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Table Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Sales reserves and allowances Sales Reserves And Allowances The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection. Royalty Pharma Royalty Pharma [Member] Royalty pharma. Non-PEO NEO Non-PEO NEO [Member] Exit And Disposal [Domain] Exit And Disposal [Domain] Exit And Disposal [Domain] Paragard Paragard [Member] Paragard Cost of sales Cost of Product and Service Sold Forward starting interest rate swaps and treasury lock agreements losses Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses Forward starting interest rate swaps and treasury lock agreements losses. SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Award Timing Method Award Timing Method [Text Block] Other Product and Service, Other [Member] Net change in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Net income (loss) attributable to Teva Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Balance Sheet Location [Axis] Location, Statement of Financial Position, Balance [Axis] Method of treatment patent Lilly Galcanezumab Product, Method of Treatment Patent [Member] Lilly Galcanezumab Product, Method of Treatment Patent Restatement Determination Date: Restatement Determination Date [Axis] Accumulated Other Comprehensive Income/(Loss) (Net of Tax) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Litigation settlement amount Litigation Settlement, Amount Awarded to Other Party Goodwill reclassified as assets held for sale Goodwill, Transfers Phase 3 funding option amount Phase3FundingOptionAmount Phase 3 funding option amount. New claims filed Loss Contingency, New Claims Filed, Number Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Weighted average number of shares (in millions): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Asset Acquisition [Table] Asset Acquisition [Table] Range [Domain] Statistical Measurement [Domain] Modafinil settlement agreement Modafinil Settlement Agreement [Member] Modafinil settlement agreement. Other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent Unrealized gain (loss) from derivative financial instruments, net Unrealized gain (loss) on derivative net of tax Unrealized gain (loss) on derivative net of tax. Document Fiscal Year Focus Document Fiscal Year Focus Loss contingency claims dismissed value paid to each State proportional to its share of national population Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population Loss contingency claims dismissed value paid to each state proportional to its share of national population Diluted earnings (loss) attributable to Teva’s ordinary shareholders (numerator): Net Income (Loss) Available to Common Stockholders, Diluted, Operations [Abstract] Ordinary shares of NIS 0.10 par value per share; September 30, 2026 and December 31, 2025: authorized 2,495 million shares; issued 1,272 million shares and 1,257 million shares, respectively. Common Stock, Value, Issued Restatement Determination Date Restatement Determination Date Percentgae of amount in cash settlement Litigation settlement amount payable in cash percentage Litigation settlement amount payable in cash percentage Eli Lilly Eli Lilly [Member] Eli Lilly Amendment Flag Amendment Flag Goodwill [Line Items] Goodwill [Line Items] Current liabilities: Liabilities, Current [Abstract] Sustainability-linked senior notes USD 1,000 million Sustainability Linked Senior Notes Due 2029 [Member] Sustainability linked senior notes due 2029. Senior notes USD 700 million Senior Notes USD 700 million [Member] Senior notes USD 700 million [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Loss Contingencies [Table] Loss Contingencies [Table] Not discontinued operations Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Employee termination costs Employee Termination [Member] Employee termination. MODAG Modag [Member] Modag . Total long-term liabilities Liabilities, Noncurrent Sustainability-linked senior notes EUR 500 million Sustainability Linked Senior Notes Due 2031 One [Member] Sustainability linked senior notes due 2031 one. Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Senior notes USD 1,200 million Senior Notes USD 1200 Million, Due 2032 [Member] Senior Notes USD 1200 Million, Due 2032 Number of plaintiffs Loss Contingency, Number of Plaintiffs Purchases of in-process research and development Payments to Acquire Equity Securities, FV-NI PEO Total Compensation Amount PEO Total Compensation Amount Currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Derivative notional amount Derivative, Notional Amount Basic (in shares) Weighted average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Certain transactions Certain Transactions Disclosure [Text Block] This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Accumulated goodwill impairment Goodwill, Impaired, Accumulated Impairment Loss Loss Contingencies [Line Items] Loss Contingencies [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Deferred income taxes Asset Acquisition, Deferred Income Taxes Asset Acquisition, Deferred Income Taxes Senior notes USD 500 million Senior Notes USD 500 million [Member] Senior notes USD 500 million [Member] Total consideration allocated Asset Acquisition, Consideration Transferred Total assets of the disposal group classified as held for sale in the consolidated balance sheets Disposal Group, Including Discontinued Operation, Assets Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Debt issuance costs Debt Issuance Costs, Gross Net income (loss) attributable to Teva’s ordinary shareholders Net Income (Loss) Available to Common Stockholders, Basic Litigation settlement amount distributable in kind Litigation Settlement Amount DistributableIn Kind Litigation settlement amount distributableIn kind. Summary of Sales Reserves and Allowances Sales Reserves And Allowances Current [Table Text Block] Tabular disclosure of sales reserves and allowances current. Unrealized loss on defined benefit plans Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax Accumulated amortization Intangible Asset, Finite-Lived, Accumulated Amortization Inventories Disposal Group, Including Discontinued Operation, Inventory, Current Collaborative agreement milestone payments, period Collaborative Agreement Milestone Payments, Period Collaborative Agreement Milestone Payments, Period Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Current maturities of long-term liabilities Long-Term Debt, Current Maturities Impairment of long-lived assets and assets held for sale Impairment Of Long Lived Assets And Assets Held For Sale Finite And Indefinite Lived Intangible Assets Other Than Goodwill Impairment of long lived assets and assets held for sale finite and indefinite lived intangible assets other than goodwill. Other Other Restructuring [Member] Sustainability-linked senior notes USD 600 million Sustainability Linked Senior Notes Due 2029 One [Member] Sustainability linked senior notes due 2029 one. Location, Statement of Other Comprehensive Income, Balance [Axis] Location, Statement of Other Comprehensive Income, Balance [Axis] Utilization and other Utilization And Other Utilization and other. Annual sales Annual Sales Annual sales of effexor. Ontario teachers securities litigation Ontario Teachers Securities Litigation [Member] Ontario teachers securities litigation. Treasury shares as of September 30, 2026 and December 31, 2025 : 105 million ordinary shares and 107 million ordinary shares, respectively Treasury Stock, Value Recently adopted accounting policies, recently issued accounting pronouncements, not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Non-controlling interests Noncontrolling Interest [Member] Amortization of debt issuance costs Amortization of Debt Issuance Costs Milestone payment one Milestone Payment, Payment One Milestone Payment, Payment One Other third parties milestone payment Other Third Parties Milestone Payment [Member] Other Third Parties Milestone Payment Net other comprehensive income (loss) before tax Other Comprehensive Income (Loss), before Tax Reimbursement of research and development expenses incurred Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Net change in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Revlimid Revlimid [Member] Annual sales of revlimid. Agreement [Domain] Agreement [Domain] Agreement. Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] UZEDY UZEDY [Member] UZEDY [Member] Accumulated other comprehensive income (loss) Equity [Text Block] Security Exchange Name Security Exchange Name Collaborative agreement milestone payments Collaborative Agreement Milestone Payments Collaborative Agreement Milestone Payments Statement of Comprehensive Income [Abstract] Summary of Financial Instrument Measured on a Basis Other Than Fair Value Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Name Outstanding Recovery, Individual Name Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Increase in development funding commitment Increase in development funding commitment Increase in development funding commitment. Beneficial interest collected in exchange for securitized trade receivables Proceeds From Beneficial Interest In Exchange For Securitized Accounts Receivables Proceeds from beneficial interest in exchange for securitized accounts receivables. Geographical [Domain] Geographical [Domain] Noncash or Part Noncash Acquisitions [Line Items] Noncash or Part Noncash Acquisitions [Line Items] Eagle transaction Eagle Transaction [Member] Eagle transaction. Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Shares (denominator): Weighted Average Number of Shares Outstanding, Basic [Abstract] Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Table Text Block] Disclosure in tabular form of pretax gain loss cash flow hedging instruments. Israel Tax Authority Israel Tax Authority [Member] Actuarial gains (losses) and prior service (costs) credits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Asset Class [Domain] Asset Class [Domain] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Compensation Amount Outstanding Recovery Compensation Amount Loss contingency accrual, product liability, undiscounted, to be paid, year two Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Two Individual: Individual [Axis] Diluted (in shares) Total dilutive shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Alvotech Alvotech [Member] Alvotech. Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Allergan transaction Allergan transaction [Member] Allergan transaction [Member] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Derivative instruments and hedging activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Net loss (gain) from sale of business and long-lived assets Profit (Loss) From Sale Of Long Lived Assets And Investment Profit from sale of long lived assets and investment. Convertible debentures Short-Term Debt Liability derivatives: Derivative Liability, Subject to Master Netting Arrangement, before Offset Revenue from Contract with Customer [Abstract] Other current assets Asset Acquisition, Other Current Assets Asset Acquisition, Other Current Assets Impairments of long-lived tangible assets Long-Lived Asset, Held and Used, Impairment Loss Other Other [Member] Other restricted cash. Treasury shares Treasury Stock, Common [Member] Intangible Asset, Goodwill and Other [Abstract] Sustainability-linked senior notes EUR 1,100 million Sustainability Linked Senior Notes Due 2027 One [Member] Sustainability linked senior notes due 2027 one. Schedule of Long-term Debt Long Term Debt Excluding Convertible Debt [Table Text Block] A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation. Organization, Consolidation and Presentation of Financial Statements [Abstract] Litigation Status [Domain] Litigation Status [Domain] Contingent liability Asset Acquisition, Contingent Consideration, Liability All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Intangible Asset, Excluding Goodwill, Impairment Loss, Statement of Income or Comprehensive Income [Extensible Enumeration] Intangible Asset, Excluding Goodwill, Impairment Loss, Statement of Income or Comprehensive Income [Extensible Enumeration] Senior notes USD 1,000 million Senior Notes USD 1000 Million, Due 2034 [Member] Senior Notes USD 1000 Million, Due 2034 Factoring Institution [Domain] Factoring Institution [Domain] Factoring institution. Asset Acquisition [Domain] Asset Acquisition [Domain] Impairments of property, plant and equipment Tangible Asset Impairment Charges Summary of Components of Restructuring Costs Schedule of Restructuring Charges [Table Text Block] Schedule of Restructuring Charges [Table Text Block] Selling and marketing expenses S&M expenses Selling and Marketing Expense Xifaxan Xifaxan [Member] Annual Sales Of Xifaxan Schedule of Earnings (Loss) per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Accounts receivable securitization facility Accounts Receivable Securitization Facility [Member] Accounts receivable securitization facility. Debt Disclosure [Abstract] Milestone payment receivable Milestone Payment Receivable Milestone payment receivable. Segments Segment Reporting [Text Block] Minimum Minimum [Member] Purchase of shares from redeemable and non-redeemable non-controlling interests Proceeds From (Payment s to) Minority Non Controlling Shareholders Proceed from Minority Non-Controlling Shareholders. Investment in securities: Investments, Fair Value Disclosure Summary of Disaggregates Revenues by Major Revenue Streams Disaggregation of Revenue [Table Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Composition of matter patent Lilly Galcanezumab Product, Composition of Matter Patent [Member] Lilly Galcanezumab Product, Composition of Matter Patent Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Patents found infringed Loss Contingency, Patents Found Infringed, Number Business Combination [Line Items] Business Combination [Line Items] Income Tax [Table] Income Tax [Table] Income Tax [Table] Milestone payment Milestone Payment Milestone payment. Other current assets Disposal Group, Including Discontinued Operation, Other Assets, Current Ordinary shares, authorized (in shares) Common Stock, Shares Authorized Amortization of intangible assets useful life Intangible Asset, Finite-Lived, Useful Life Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Regulatory price and volume of products Regulatory Price And Volume Of Products [Member] Regulatory price and volume of products. Exercise Price Award Exercise Price Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Reissuance of treasury shares for stock compensation plans Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Settled litigation Settled Litigation [Member] Income (loss) before income taxes Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Loss contingency accrual due in fourth year Loss Contingency Accrual Due In Fourth Year Loss contingency accrual due in fourth year. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Beginning balance Ending balance Restructuring Reserve Equity Component [Domain] Equity Component [Domain] Measurement Input Type [Domain] Measurement Input Type [Domain] Options and forward contracts Foreign Exchange Contract [Member] Adoption Date Trading Arrangement Adoption Date Counterparty Name [Domain] Counterparty Name [Domain] Financial expenses, net Nonoperating Income (Expense) Restructuring Type [Axis] Restructuring Type [Axis] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Event Basis [Domain] Event Basis [Domain] Event basis . Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Other Other Sales Reserves And Allowances [Member] Other sales reserves and allowances. Other financing activities Proceeds from (Payment for) Other Financing Activity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Damages awarded Loss Contingency, Damages Awarded, Value Type of Restructuring [Domain] Type of Restructuring [Domain] Business Acquisition, Acquiree [Domain] Business Combination [Domain] Purchase of shares from redeemable non-controlling interests Noncontrolling Interest, Increase from Subsidiary Equity Issuance Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Weighted average Weighted Average [Member] Less debt issuance costs Debt Issuance Costs, Noncurrent, Net All Adjustments to Compensation All Adjustments to Compensation [Member] Other items Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Business Acquisition [Axis] Business Combination [Axis] Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Release of cumulative translation adjustments Release from Accumulated Other Comprehensive Income of Cumulative Translation Adjustments, Before Tax Release of cumulative translation adjustments. Accounts receivable Accounts Receivable [Member] Income Statement [Abstract] Teva shareholders’ equity: Equity, Attributable to Parent [Abstract] Development and launch milestone payment receivable Development and Launch Milestone Payment Receivable Development and launch milestone payment receivable. Document Transition Report Document Transition Report Trade payables, accrued expenses, employee-related obligations and other liabilities Increase (Decrease) in Operating Liabilities Loss contingency accrual, product liability, undiscounted, to be paid, year three Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Three Expected loss on sale Expected Loss From Reclassification of Currency Translation Adjustments Expected Loss From Reclassification of Currency Translation Adjustments BNP Paribas Bank BNP Paribas Bank [Member] BNP Paribas Bank Deferred income taxes Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] License agreement potential aggregate milestone payments amount License Agreement Potential Aggregate Milestone Payments Amount License agreement potential aggregate milestone payments amount. Summary of Identifiable Intangible Assets Intangible Asset, Finite-Lived [Table Text Block] Other Commitments [Domain] Other Commitments [Domain] City Area Code City Area Code Generic products (including biosimilars) Generics Medicians Including OTC And Biosimilars [Member] Generics medicians including OTC and biosimilars. Total Debt Instrument, Fair Value Disclosure Collaborative arrangement Collaborative Arrangement [Member] Name Forgone Recovery, Individual Name Accrued expenses Accrued Expenses Accrued expenses. Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Donation of Clotrimazole and Tobramycin Donation of Clotrimazole and Tobramycin [Member] Donation of clotrimazole and tobramycin. Accrual for environmental loss contingencies Accrual for Environmental Loss Contingencies Updated market assumptions Updated Market Assumptions [Member] Updated market assumptions . Minimum tax rate Minimum Tax Rate Minimum tax rate. Total Fair Value, Net Asset (Liability) Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, before Tax Issuance of Shares (in shares) Stock Issued During Period, Shares, New Issues Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Polpharma Polpharma Biologics International AG [Member] Polpharma Biologics International AG Product Information [Line Items] Product Information [Line Items] Other liabilities Asset Acquisition, Other Liabilities Asset Acquisition, Other Liabilities Subsequent Event Type [Domain] Subsequent Event Type [Domain] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Milestone payment percentage cap Milestone Payment, Percentage Cap Milestone payment percentage cap. Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Emalex Biosciences Emalex Biosciences [Member] Emalex Biosciences [Member] Entity Current Reporting Status Entity Current Reporting Status Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Matthew Shields [Member] Matthew Shields Total Shareholder Return Amount Total Shareholder Return Amount Other current liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Current Net change in operating assets and liabilities Net change in operating assets and liabilities Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital Adjustments to reconcile net income (loss) to net cash provided by operations: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] 5.75% Senior notes due 2030 Five Point Seven Five Senior Notes Due 2030 [Member] 5.75% senior notes due 2030. Financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property, plant and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Litigation fine amount Litigation Fine Amount Litigation fine amount of copaxone. Other commitment, to be paid, year five Other Commitment, to be Paid, Year Five Cash consideration for outstanding shares, net of working capital adjustments Asset Acquisition Consideration Transferred Cash Asset Acquisition Consideration Transferred Cash Chargebacks Chargebacks [Member] Chargebacks. Asset derivatives: Derivative Asset Inventories Inventory Disclosure [Text Block] Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] Proceeds from exercise of options Stock Issued During Period, Value, Stock Options Exercised Underlying Securities Award Underlying Securities Amount Comprehensive income (loss) attributable to redeemable and non-redeemable non-controlling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Revenue from contracts with customers Revenue from Contract with Customer [Text Block] Issuance of shares Stock Issued During Period, Value, New Issues Prepaid expenses Prepaid Expense, Current 5.25% Senior notes due 2032 Five Point Two Five Senior Notes Due 2032 [Member] Five Point Two Five Senior Notes Due 2032 Inventories Increase (Decrease) in Inventories Other investing activities Payment for (Proceeds from) Other Investing Activity Segment Reporting [Table] Segment Reporting [Table] Other current assets Other Assets, Current Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Fair value at the beginning of the period Fair value at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Current Fiscal Year End Date Current Fiscal Year End Date Expenses recorded Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Derivative [Line Items] Derivative [Line Items] Loss contingency accrual remainder of fiscal year Loss Contingency Accrual Remainder Of Fiscal Year Loss contingency accrual remainder of fiscal year. Other non-current liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Dividend to non-controlling interest Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Total senior notes Senior Notes Other Other Products [Member] Other Products [Member] Measure: Measure [Axis] Percentage of share of national population Percentage Of Share Of The National Population Percentage of share of the national population. Proceeds from senior notes, net of issuance costs Proceeds From (Repayments Of) Senior Notes, Net of Issuance Costs Proceeds From (Repayments Of) Senior Notes, Net of Issuance Costs Treasury shares (in shares) Treasury Stock, Common, Shares Novetide transaction Nove Tide Acquisition [Member] Nove tide acquisition. Deferred income taxes – net and uncertain tax positions Deferred Income Taxes Net And Uncertain Tax Positions Deferred income taxes net and uncertain tax positions. Equity Components [Axis] Equity Components [Axis] Asset Acquisition Asset Acquisition [Table Text Block] Medicaid and other governmental allowances Medicaid And Other Governmental Allowances [Member] Medicaid and other governmental allowances. Entity Interactive Data Current Entity Interactive Data Current Net income (loss) attributable to redeemable and non-redeemable non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Smaller Reporting Company Entity Small Business Comprehensive income (loss) attributable to Teva Comprehensive Income (Loss), Net of Tax, Attributable to Parent Samsung Bioepis Samsung Bioepis [Member] Samsung Bioepis Settlement of contingent consideration: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Event Basis [Axis] Event Basis [Axis] Event basis . Other non-current assets Other Assets, Noncurrent Document Type Document Type Revenue Recognition [Line Items] Revenue Recognition [Line Items] Revenue Recognition [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt BENDEKA and TREANDA BENDEKA and TREANDA [Member] BENDEKA and TREANDA. Impairment of intangible assets excluding goodwill Intangible Asset, Excluding Goodwill, Impairment Loss Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Atripla Atripla [Member] Annual sales of the time of settlement of atripla. Aggregate cap per company Milestone Payment, Aggregate Cap Per Company Milestone Payment, Aggregate Cap Per Company Direct purchaser plaintiffs Cases of Direct Purchaser Plaintiffs Cases of Direct Purchaser Plaintiffs Commitments and contingencies, see note 10 Commitments and Contingencies Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Sanofi Sanofi [Member] Sanofi. Executive Category: Executive Category [Axis] Corresponding income tax Other Comprehensive Income (Loss), Tax Counterparty Name [Axis] Counterparty Name [Axis] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Other Commitments [Table] Other Commitments [Table] Inventories Total Inventory, Net Dr. Eric Hughes [Member] Dr. Eric Hughes Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Non-cash financing and investing activities: Supplemental Cash Flow Information [Abstract] Facility [Axis] Facility [Axis] Facility. Senior notes and loans Notes and Loans, Noncurrent PEO Name PEO Name Derivative financial instruments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Other unallocated amounts Segment Reporting, Other Segment Item, Amount Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Business combination, contingent consideration, liability, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Loss contingencies on environmental laws penalty Loss Contingencies On Environmental Laws Penalty Loss contingencies on environmental laws penalty. Effexor Effexor [Member] Effexor Number of complaints Loss Contingency, Number of Complaints Annual sales of the time of new launch of viread. Other Commitments [Line Items] Other Commitments [Line Items] Identifiable intangible assets, net Disposal Group, Including Discontinued Operation, Intangible Assets, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Intangible assets impairments Intangible Asset Impairments Intangible Asset Impairments. Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Factoring Institution [Axis] Factoring Institution [Axis] Factoring institution. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Debt Instrument [Axis] Debt Instrument [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Disposal Group Name [Axis] Disposal Group Name [Axis] 2008 through tax payable Two Thousand Eight Through Tax Payable [Member] Two thousand eight through tax payable . Summary of Classification and Fair Values of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Basic (in dollars per share) Basic earnings (loss) attributable to Teva's ordinary shareholders (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Accrued expenses Asset Acquisition, Accrued Expenses Asset Acquisition, Accrued Expenses Total current assets Assets, Current Insider Trading Arrangements [Line Items] Facility [Domain] Facility [Domain] Facility. Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Additional development and milestone payments receivable Additional Development And Milestone Payments Receivable Additional development and milestone payments receivable. Accounts receivables, net of allowance for credit losses of $71 million and $81 million as of September 30, 2026 and December 31, 2025, respectively. Accounts receivables sold Accounts Receivable, after Allowance for Credit Loss, Current Milestone payment to be paid Milestone Payment To Be Paid Milestone payment to be paid. Schedule of Short-term Debt Schedule of Short-Term Debt [Table Text Block] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Contingent consideration Business Combination, Contingent Consideration, Liability Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Loss contingency accrual, product liability, undiscounted, to be paid, year four Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Four Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Weighted average interest rate Short-Term Debt, Weighted Average Interest Rate, at Point in Time Litigation settlement amount awarded distribution period Litigation Settlement Amount Awarded Distribution Period Litigation settlement amount awarded distribution period. Equity Awards Adjustments Equity Awards Adjustments [Member] Number of Competition and Markets Authority investigations agreed to indemnity Number of Competition and Markets Authority Investigations Agreed to Indemnity Number of Competition and Markets Authority Investigations Agreed to Indemnity Asset Acquisition [Line Items] Asset Acquisition [Line Items] Certain Transactions [Line Items] Certain Transactions [Line Items] Certain Transactions [Line Items] Short-term debt Short-term debt Debt, Current Litigation settlement amount distributable in cash Litigation Settlement Amount Distributable in Cash Litigation settlement amount distributable in cash. Inventory Disclosure [Abstract] Loss contingency accrual, provision Loss Contingency Accrual, Loss (Reversal of Loss) Candidates with line extensions Number of Candidates With Line Extensions Number of Candidates With Line Extensions Total Teva shareholders' equity Parent [Member] Equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Entity Address, Country Entity Address, Country General and administrative expenses G&A expenses General and Administrative Expense Civil action in respect of donations to Patient Assistance Programmers Civil Action In Respect Of Donations To Patient Assistance Programmers [Member] Civil action in respect of donations to patient assistance programmers. COPAXONE COPAXONE [Member] COPAXONE. Number of Competition and Markets Authority investigations Number of Competition and Markets Authority Investigations Annual sales of the time of new launch of Atripla. Pending claims Loss Contingency, Pending Claims, Number Hedging Designation [Domain] Hedging Designation [Domain] Statement of Cash Flows [Abstract] Other commitment Other Commitment In process research and development In process research and development In Process Research and Development [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Revenues other than USD Revenues Other Than Usd Revenues other than US Dollar. Expected positions eliminated, percent Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent Income taxes Income Tax Disclosure [Text Block] Period [Domain] Period [Domain] Period domain. Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Entity Filer Category Entity Filer Category Cash, deposits and other Cash, Deposits and Other [Member] Cash, Deposits and Other Revision of Prior Period [Axis] Revision of Prior Period [Axis] Senior notes EUR 750 million Subsidiary Senior Notes Due 2028 One [Member] Subsidiary Senior Notes Due 2028 One [Member] Gain (loss) from derivatives Gain (Loss) on Derivative Instruments, Net, Pretax Not designated as hedging instruments Line items in which effects of hedges are recorded Not Designated as Hedging Instrument [Member] Acquired IPR&D Asset Acquisition, Acquired In Process Research and Development Assets Asset Acquisition, Acquired In Process Research and Development Assets Entity Address, Address Line Two Entity Address, Address Line Two Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Current assets: Assets, Current [Abstract] Liability derivatives: Derivative Liability Senior notes Senior Notes [Member] Entity Address, Address Line One Entity Address, Address Line One Income taxes (benefit) Tax benefit Income Tax Expense (Benefit) Trade receivables net of sales reserves and allowances Increase Decrease In Certain Current Assets Excluding Inventories Increase decrease in certain current assets excluding inventories. Leverage ratio Leverage Ratio Leverage ratio. Loss contingency accrual current Loss Contingency, Accrual, Current Research and development expenses R&D expenses Research and Development Expense (Excluding Acquired in Process Cost) Statement [Table] Statement [Table] Other Activities Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Restructuring And Impairment [Abstract] Restructuring and impairment. Derivatives term of contract Derivative, Contract Term Percentage of increase decrease in contingent consideration liabilities Business Combination, Contingent Consideration, Liability, Measurement Input Change Percentage of increase decrease in contingent consideration liabilities. Number of indictment charges Loss Contingency, Number of Indictment Charges Annual sales of the time of New launch of truvada. Total identifiable assets and liabilities acquired Asset Acquisition, Identifiable Assets And Liabilities Acquired Net Asset Acquisition, Identifiable Assets And Liabilities Acquired Net Asset derivatives: Derivative Asset, Subject to Master Netting Arrangement, before Offset Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Convertible debentures Short Credit Agreement 2026 [Member] Short credit agreement 2026. Basis of presentation Basis of Presentation and Significant Accounting Policies [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract]